Price
No data yet.
Social Signal Score
Revenue
$639.49M+86.81%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Uwe Ferdinand Röhrhoff
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 13,528
- Beta
- 0.47
- Country
- DE
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 0.97
Financials
Revenue
$639.49M+86.8%Net Income
$-306.63M-1987.5%EBITDA
$80.36M+27.4%Free Cash Flow
$31.82MEPS (diluted)
$-8.88-1807.7%Shares Outstanding (diluted)
34.54M+10.6%Operating Expenses
$200.24MCash & Debt
$176.21MReturn of Capital
$975.0KDividend per Share
$0.05Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.32B | $-320.32M | $-9.27 |
| 2024 | $2.04B | $109.72M | $3.18 |
| 2023 | $1.99B | $116.13M | $3.48 |
| 2022 | $1.82B | $96.12M | $3.06 |
| 2021 | $1.50B | $83.79M | $2.67 |
| 2020 | $1.42B | $88.56M | $2.82 |
| 2019 | $1.39B | $80.78M | $2.57 |
| 2018 | $1.37B | $128.97M | $4.11 |
| 2017 | $1.35B | $100.89M | $3.21 |
| 2016 | $1.38B | $121.64M | $3.87 |
| 2015 | $1.38B | $104.22M | $3.32 |
| 2014 | $1.29B | $66.34M | $2.11 |
| 2013 | $1.27B | $62.16M | $1.98 |
| 2012 | $1.22B | $62.02M | $1.98 |
Valuation
GRRMFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70Social Signal Score
Mentions (1)
- Newsmarketbeat.com·5h ago·Negative
Gerresheimer Q1 Earnings Call Highlights Gerresheimer ETR: GXI reported preliminary first-quarter 2026 results that showed modest revenue growth but lower earnings as the packaging and drug-delivery company prioritized cash preservation, reduced capital spending and limited inventory buildup.
View source ↗
Earnings
Fri, Aug 28(today)
Consensus estimate $-0.39 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Mar 31$0.38 vs $0.38beat
- Wed, Feb 25$-0.07 vs $-0.07beat
- Fri, Oct 10$0.81 vs $0.95miss
- Thu, Jul 10$1.02 vs $0.92beat
- Fri, Apr 11$0.48 vs $0.25beat
Estimates and results for GRRMF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.